XL413 (BMS-863233)

For research use only.

Catalog No.S7547

12 publications

XL413 (BMS-863233) Chemical Structure

CAS No. 1169562-71-3

XL413 (BMS-863233) is a potent and selective cell division cycle 7 homolog (CDC7) kinase inhibitor with IC50 of 3.4 nM, showing 63-, 12- and 35-fold selectivity over CK2, Pim-1 and pMCM2, respectively. Phase 1/2.

Selleck's XL413 (BMS-863233) has been cited by 12 publications

2 Customer Reviews

  • The protein levels of p-MCM2 and p-ERK in NOK, HN6 and Cal27 cells treated with 0, 10 and 20 μMXL413 were detected by western blotting.

    J Mol Med, 2018, 96(6):513-525. XL413 (BMS-863233) purchased from Selleck.

    Effects of XL413 plus pirfenidone on 10T1/2 cells morphology, proliferation and TGF-β1-induced α-SMA expression. Cells were exposed to control, XL413 (10 μM), pirfenidone (1 mg/ml) or XL413 plus pirfenidone. (G) Laser confocal scanning was used for visualization of α-SMA protein expression and cellular morphological changes.

    Exp Cell Res, 2015, 339(2):289-99.. XL413 (BMS-863233) purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description XL413 (BMS-863233) is a potent and selective cell division cycle 7 homolog (CDC7) kinase inhibitor with IC50 of 3.4 nM, showing 63-, 12- and 35-fold selectivity over CK2, Pim-1 and pMCM2, respectively. Phase 1/2.
Cdc7 [1]
(Cell-free assay)
Pim1 [1]
(Cell-free assay)
CK2 [1]
(Cell-free assay)
3.4 nM 42 nM 212 nM
In vitro

In MDA-MB-231T and Colo-205 cell lines, XL413 results in inhibition of CDC7 specific phosphorylation of MCM2. XL413 also inhibits the cell proliferation, decreases cell viability and elicits the caspase 3/7 activity in Colo-205 cells. Moreover, XL413 results in modified S phase progression that subsequently leads to apoptotic cell death. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-231T cells NIn5N|BHfW6ldHnvckBie3OjeR?= M{fXe|QhcA>? NF;2foxKdmirYnn0bY9vKG:oIFPER|chcW5iaIXtZY4hVUSDLV3CMVI{OVRiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBOS01{IIDoc5NxcG:{eXzheIlwdiCjdDDT[ZI2OyCjZoTldkA1KGi{czygTWM2OD1yLkGxPEDPxE1? NXHFe|J{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OlA2PjdpPkKyOVYxPTZ5PD;hQi=>
human Caco2 cells NWnLcW1kTnWwY4Tpc44h[XO|YYm= MUm0JIg> MWXJcohq[mm2aX;uJI9nKEOGQ{egbY4hcHWvYX6gR4FkdzJiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBOS01{IIDoc5NxcG:{eXzheIlwdiCjdDDT[ZI2OyCjZoTldkA1KGi{czygTWM2OD1yLkG0JO69VQ>? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV4MEW2O{c,OjJ3NkC1Olc9N2F-
human Caco2 cells M3fBRnBzd2yrZnXyZZRqd25iYYPzZZk> NFXn[|FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPhZ48zKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZY5kcG:{YXflMYlv\GWyZX7k[Y51KGe{b4f0bEBqdiC|b3\0JIFo[XJuIFnDOVA:OC55MUWg{txO MlfkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NkC1OlcoRjJ{NU[wOVY4RC:jPh?=
Caco2 cells MmiwSpVv[3Srb36gZZN{[Xl? MUnJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEOjY3:yJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGOjc4Dhd4UhOy95IHHjeIl3cXS7LDDFR|UxRTJwMki4JO69VQ>? NVuycFBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OlA2PjdpPkKyOVYxPTZ5PD;hQi=>
MDA-MB-468 NVnhZ3hITnWwY4Tpc44h[XO|YYm= NFXtb2lKdmirYnn0bY9vKG:oIGDIS2RJKGmwIHj1cYFvKE2GQT3NRk01PjhiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gd4VzcW6nIH\seZgtKEWFNUCgQUAzNjNizszNMi=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV3NUSxPUc,Ojl3NUW0NVk9N2F-
MDA-MB-468 NIDGNXVEgXSxdH;4bYNqfHliYYPzZZk> Mk\DR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczygSWM2OCB;IEig{txONg>? NWqy[40{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OVU1OTlpPkK5OVU2PDF7PD;hQi=>

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
p-Mcm2 / Mcm2; 

PubMed: 25412417     

(A) Immunoblots showing Mcm2 phosphorylation in HCC1954 cells or (C) Colo-205 cells in the presence of DMSO, PHA-767491, or XL413. XL413 is defective in inhibiting DDK-dependent Mcm2 phosphorylation in HCC1954 cells but is effective in Colo-205 cells.

In vivo In a Colo-205 xenograft model, XL413, at the 3 mg/kg dose, causes 70% inhibition of phosphorylated MCM2, and causes significant tumor growth regression at the 100 mg/kg dose. [1]


Kinase Assay:


- Collapse

CDC7 kinase assay :

Kinase activity and compound inhibition are determined using the luciferase-luciferin-coupled chemiluminescence assay and measured as the percentage of ATP utilized following the kinase reaction in a 384-well format. The final CDC7 kinase assay condition is 6 nM CDC7/ASK, 1 μM ATP, 50 mM Hepes pH 7.4, 10 mM MgCl2, 0.02% BSA, 0.02% brij 35, 0.02% tween 20 and 1 mM DTT. It is worthy to note that the CDC7/ASK protein exhibits substrate-independent ATP utilization. All kinase reactions are incubated at room temperature for 1-2 h.
Cell Research:


- Collapse
  • Cell lines: Colo-205 cells
  • Concentrations: ~10 μM
  • Incubation Time: 24 hours
  • Method:

    The cell proliferation is measured by BrdU incorporation assay, and viability is assayed by Cell Titer–Glo kits.

    (Only for Reference)
Animal Research:


- Collapse
  • Animal Models: Mice bearing Colo-205 xenografts
  • Dosages: ~100 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro Water 46 mg/mL warmed (141.02 mM)
DMSO Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 326.18


CAS No. 1169562-71-3
Storage powder
in solvent
Synonyms N/A
Smiles C1CC(NC1)C2=NC3=C(C(=O)N2)OC4=C3C=C(C=C4)Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00886782 Terminated Drug: Cdc7-inhibitor Advanced Solid Cancers|Metastatic Cancer Bristol-Myers Squibb|Exelixis May 2009 Phase 1|Phase 2
NCT00838890 Terminated Drug: Cdc7-inhibitor (BMS-863233) Refractory Hematologic Cancer Bristol-Myers Squibb|Exelixis March 2009 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

Related CDK Products

Tags: buy XL413 (BMS-863233) | XL413 (BMS-863233) supplier | purchase XL413 (BMS-863233) | XL413 (BMS-863233) cost | XL413 (BMS-863233) manufacturer | order XL413 (BMS-863233) | XL413 (BMS-863233) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID